240 - CCPN SPOTLIGHT: JOURNEY THROUGH THE CARDIOVASCULAR DISEASE CONTINUUM

Friday, October 25, 2024

2:00 PM – 3:00 PM PT

Room:111-112

Target Audience: General: All cardiovascular (clinical and research) health professionals

Co-Chair(s)

Emily Cowley, PharmD

Hospital Pharmacist
CCPN
MG

Marie-France Gauthier, PharmD

Clinical Pharmacist
CCPN
Université de Montréal

Presenter(s)

Marc Bains, BBA

Co-Founder, HeartLife Foundation of Canada
HeartLife / Canadian Heart Function Alliance
Krystyna Edwards-Lee, PharmD

Clinical Resource Pharmacist- New Brunswick Heart Centre
CCPN
Ricky Turgeon, PharmD (he/him/his)

Assistant Professor
University of British Columbia

Panelist(s)

Marc Bains, BBA

Co-Founder, HeartLife Foundation of Canada
HeartLife / Canadian Heart Function Alliance
DO

Deirdre O'Neill, MD

Cardiologist
n/a
Ricky Turgeon, PharmD (he/him/his)

Assistant Professor
University of British Columbia

Planning Committee Member(s)

MG

Marie-France Gauthier, PharmD

Clinical Pharmacist
CCPN
Université de Montréal

Workshop Description: The cardiovascular continuum follows patients through a progressive sequence of events beginning with risk factors and leading to end stage heart disease. With the evolving demands of patients with chronic and complex conditions, intervention within the sequence of events can be challenging and requires collaborative partnerships. This workshop is presented by the Canadian Cardiovascular Pharmacists Network. This session will lead audience members through common scenarios within a patient’s journey in the healthcare system and highlight opportunities for patient-specific interventions. Where applicable, CCS guidelines will be summarized and applied. Interactive components will include polling, panel discussion and a Q&A period.

Interactive and Engagement Activities Description: This workshop will utilize a real-life patient scenario and integrate polling questions throughout each segment to engage audience members in-person and virtually. There will be approximately 2-4 questions embedded within each section. At the end of the workshop, 15 minutes will be allocated for a question and answer period at the end of the workshop. Audience members will have the opportunity to ask questions, discuss the case with colleagues and share their own experiences with the attendees. If there are no audience questions, the Chair will moderate the panel discussion with questions.

Learning Objectives:

At the end of this session participants will be able to:

describe the risk of ketoacidosis and urinary tract infections associated with SGLT2i and clarify when this medication class should be avoided;
recognize key non-cardiovascular medications that can cause or worsen heart failure and consider treatment alternatives;
identify the risks and benefits of the use of guideline directed medical therapy in renal dysfunction;
discuss common issues faced in clinical practice with up-titration of guideline directed medical therapy using real patient scenarios; and
describe the importance of patient’s perspectives related to their experience with HF.

Presentations:

2:55 PM – 3:00 PM PT

PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF DIABETES MEDICATION WITH CARDIORENAL BENEFIT: A POPULATION-BASED ANALYSIS FROM ALBERTA, CANADA
Presenter: Rahim Kanji, BScN, MD Student (he/him/his) – University of Calgary, Cumming School of Medicine